SCHEMBL3318296

SCHEMBL3318296

O=C(Nc1ccc(-n2ccnc2)c(F)c1)N(Cc1ccccc1)C1=COCO1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BLM P54132 1/20 0.43
CD38 P28907 4/20 0.36
TP53 P04637 2/20 0.36
LMNA P02545 1/20 0.36
UBE2M P61081 4/20 0.35
DCUN1D1 Q96GG9 4/20 0.35
ROCK1 Q13464 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 1/20 0.34
GAA P10253 1/20 0.34
RAB9A P51151 1/20 0.34
IDH2 P48735 1/20 0.34
HTT P42858 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3316449 0.87 AAK1 (0.47) CD38UBE2MDCUN1D1MEN1KMT2A
SCHEMBL4920592 0.83 MAPT (0.42) TP53LMNAUBE2MDCUN1D1MEN1
SCHEMBL4359232 0.81 ACHE (0.39) TP53LMNAUBE2MDCUN1D1MEN1
SCHEMBL4351294 0.80 ALDH1A1 (0.39) TP53LMNAUBE2MDCUN1D1MEN1
SCHEMBL4354386 0.74 CCR2 (0.41) TP53LMNAUBE2MDCUN1D1MEN1
SCHEMBL3314880 0.72 NAMPT (0.57) BLMLMNAROCK1MEN1KMT2A
SCHEMBL4345577 0.72 HDAC3 (0.36) MEN1KMT2ANPC1GAARAB9A
SCHEMBL11027292 0.72 MST1R (0.43) UBE2MDCUN1D1
SCHEMBL4359597 0.72 LMNA (0.42) LMNAUBE2MDCUN1D1MEN1KMT2A
SCHEMBL4347969 0.72 EGFR (0.43) TP53LMNAUBE2MDCUN1D1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105904-A1 UREA TYPE CINNAMIDE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-04-29 US disclosed
EP-2019093-A1 UREA TYPE CINNAMIDE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2009-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105904-A1 UREA TYPE CINNAMIDE DERIVATIVE SLC14A1, UTS2R, MAN2B1 BLM 4392/4885CD38 1427/4885TP53 3836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.